shown to be effective in severe and refractory cases of pemphigus. 2 Meta-analysis have 23 tried to analyse its efficacy in PF, but results are based on heterogeneous case series and 24 reports. Our aim was to evaluate the clinical response to rituximab in a series of patients 25 with PF.
26
The medical records of 12 patients with PF treated with rituximab from January 2007 to 27 May 2017 were reviewed. Mean patient age was 55.75±12.4 years, and the median 28 disease duration was 46 months (range 2 months-11 years). All the patients had been 29 treated according to the European Guidelines. 1
30
After the first infusion of rituximab, 6 patients (50%) showed a complete response (CR) 31 off and 5 patients (42%) a partial response. Relapses occurred in 6 patients (50%) after a 32 median of 12 months (range 7-55 months).
33
Adverse events were reported in 4 cases (33.3%). We did not observe a trend towards 34 infection if immunosuppressive drugs or doses of prednisone higher than 10 mg/day 35 were used as comedication (p=0.627). Cumulative rituximab dose, dose per cycle or the 36 number of cycles of rituximab and sex were not associated with a greater risk of 37 infection (p=0.4777, p=69654, p=0.5758 and p=0.5301 respectively) ( Table 1) .
38
Rituximab is considered to be effective in pemphigus, with an estimated CR rate of 76-39 87% after the first cycle. [2] [3] [4] The largest published series of PF found a CR rate of 50%, 5 40 which was lower than the response rates in pemphigus vulgaris (PV), but was identical 41 to our series. These lower response rates could be the result of the selection of the most 42 severe and complicated patients, with a longer disease duration.
M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT unable to find any trends towards CR with the number of cycles, but none of our 46 patients received more than two cycles of rituximab.
Adverse events were reported in four patients (33.3%). This rate was higher than in 48 other studies in PV (24%) 4 but lower than the 42% found in the largest case series of 49 PF. 5 Patient 5 developed tuberculous meningitis, but had been treated with prednisone 50 and immunosuppressants before receiving rituximab, and it is difficult to determine if 51 this infection could only be attributed to rituximab. As well as in the series of de Sena 52 Nogueira Maehara, 5 we were unable to show that the cummulative dose or the number 53 of cycles of rituximab were associated with a risk of infection, but contrary to them 5 we 54 did not observe an association of infections with sex.
55
In conclusion, rituximab seems to be effective as a third-line therapy for patients with 
